Introduction Polymer-free drug-eluting stents are designed with stent surface modifications and drug-matrix formulations in order to release antiproliferative agents without the need of a polymer coating. Polymer-free technologies have the potential to overcome complications due to polymer persistence over time, such as local inflammatory reactions, delayed arterial healing, neoatherosclerosis, and subsequent ischemic adverse events.Areas covered The Cre8 polymer-free amphilimus-eluting stent received CE mark in 2011 and was conceived with the aim of addressing the safety and efficacy limitations of early generation drug-eluting stents based on permanent polymer coatings. Besides the absence of polymer, the main features of the Cre8 stent include the abluminal reservoirs, the passive carbon film coating, and the antiproliferative agent formulation based on sirolimus mixed with free-fatty acid chain - namely amphilimus. This review will focus on the Cre8 development, technical characteristics, preclinical evidence, clinical efficacy and safety, and future perspectives.Expert opinion The Cre8 stent has shown favorable angiographic and clinical outcomes at short and medium-term follow-up. This technology might provide a benefit in patients with diabetes. Further randomized evidence is required to provide an adequate clinical evaluation of this promising technology in patients with and without diabetes.OBJECTIVE To determine stroke prevalence, mechanisms, and long-term outcome in a cohort of Hispanic patients with systemic lupus erythematosus (SLE). METHODS We analyzed demographical data, the timing between SLE diagnosis and stroke onset, stroke type, recurrence, and outcomes from an institutional database of 4451 patients with SLE followed from 1993 to 2018. RESULTS We observed 139 strokes (3.1%), for an incidence rate of 1.25 per 1000 person-years 81 (58.3%) acute ischemic stroke (AIS), 19 (13.7%) subarachnoid hemorrhage (SAH), 17 (12.2%) cerebral venous thrombosis, 13 (9.4%) intracerebral hemorrhage (ICH), and 9 (6.5%) transient ischemic attack. Median time from SLE diagnosis to acute stroke was 60 months (interquartile range 12-132 months). AIS had a bimodal presentation with 26% occurring within the first year and 30% &gt;10 years after SLE diagnosis. In contrast, 75% of ICH cases occurred &gt;3 years (and 34% &gt;10 years) after SLE diagnosis. The most important cause of AIS was secondary antiphospholipid syndrome (48%). Hypertension was associated with 69% of ICH cases, while aneurysmal rupture was observed in 78% of SAH cases. Excellent recovery at hospital discharge was observed in 65%. Stroke recurrence was observed in 7%. The long-term all-cause fatality rate was 8%. CONCLUSIONS The prevalence of stroke in this cohort was 3.1%. Ischemic strokes had a bimodal presentation, occurring either early after SLE diagnosis or after a several-year delay. Half of the hemorrhagic strokes occurred &gt;10 years after the diagnosis of SLE. Clinical outcome was usually good with a relatively low recurrence rate.Associations of polymorphisms in vitamin D receptor (VDR) with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have already been explored by many studies. The aim of this meta-analysis was to better clarify associations between polymorphisms in VDR and RA/SLE by combing the results of all relevant studies. https://www.selleckchem.com/products/AZD8931.html Eligible studies were searched from Pubmed, Embase, WOS and CNKI. We used Review Manager to combine the results of eligible studies. Thirty-seven studies were included in this meta-analysis. VDR rs1544410 (recessive comparison odds ratio (OR)?=?1.36, 95% confidence interval (CI) 1.06-1.76; over-dominant comparison OR?=?0.81, 95% CI 0.71-0.93) and rs731236 (over-dominant comparison OR?=?0.77, 95% CI 0.63-0.94) polymorphisms were found to be significantly associated with RA in overall combined analyses. Besides, VDR rs1544410 (dominant comparison OR?=?0.61, 95% CI 0.46-0.82; over-dominant comparison OR?=?1.45, 95% CI 1.16-1.81; allele comparison OR?=?0.75, 95% CI 0.62-0.92), rs2228570 (dominant comparison OR?=?0.58, 95% CI 0.50-0.67; recessive comparison OR?=?1.57, 95% CI 1.21-2.03; allele comparison OR?=?0.69, 95% CI 0.60-0.80) and rs731236 (dominant comparison OR?=?0.69, 95% CI 0.50-0.96; allele comparison OR?=?0.80, 95% CI 0.70-0.90) polymorphisms were also found to be significantly associated with SLE in overall combined analyses. Subgroup analyses revealed that significant associations for VDR polymorphisms and RA/SLE were mainly driven by Asians. Collectively, this meta-analysis proved that VDR rs7975232, rs1544410, rs2228570 and rs731236 polymorphisms may confer susceptibility to RA and SLE, especially for Asians.Introduction Tuberculosis (TB) is still one of the major global health threats and delayed diagnosis or misdiagnosis continues to fuel the global epidemic. The conventional diagnostic approaches have shortcomings that might hinder the process of diagnosis of the disease and ultimately affect the prognosis.Area Covered We emphasize on the process of the synthesis of liposomes, its physicochemical properties affecting the formulation and their utilization in the field of molecular diagnostics for TB. The review also sheds a light on other nanoparticle-based molecular diagnostic approaches for TB. Despite the advent of science, we are yet to have a diagnostic tool that is simple, rapid, sensitive, and specific, and most importantly, one that enables us to demarcate patients with active tuberculosis from those with quiescent lesions, prior vaccination, or other diseases.Expert opinion The utility of liposomes for diagnostic purposes has been attempted so as to overcome the challenges posed by conventional diagnostic tools for Tuberculosis. Through this review we present insights into liposome formulation and selection processes, various studies that report the use of liposome-based diagnostic tools for tuberculosis, as well as the limitations associated with the same that can be improvised to make the technology more efficient.Group sequential clinical trial designs allow the sequential hypothesis testing as data is accumulated over time, while ensuring the control of type-1 error rate. These designs vary in how they split the overall type-1 error among analyses, but practically, all assume that 1. The underlying data is normal or approximately so, and 2. the sample sizes are large, so the individual test statistics are sufficiently normal rather than Student's t. These two assumptions lead to the reliance on the multivariate normal distribution for calculation of the critical values. Several publications have pointed out that for small sample sizes, such an approach leads to an inflated type-1 error and proposed different sets of critical values from either simulations or by an ad-hoc adjustment to the asymptotic critical values. In this paper, we develop the exact joint distribution of the test statistics for any sample size. We show how to calculate exact critical values that conform to some well-known alpha-spending functions, such as the O'Brien-Fleming and Pocock critical values.